Isis Pharmaceuticals to Present at Upcoming Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Investors Focused on Two Questions for ISIS Pharmaceuticals (ISIS), Needham & Company Notes
April 13, 2015 6:28 AM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and $80 price target on ISIS Pharmaceuticals (NASDAQ: ISIS) after spending several days on the road with ISIS management and found investor questions remarkably focused on two key areas.
The first area was the... More
